SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

AstraZeneca Pharma to close API Unit, Yelahanka in Bangalore

03 Dec 2015 Evaluate

AstraZeneca Pharma India has decided to close the Active Pharmaceutical Ingredient Unit (API Unit) situated at 12'h Mile on Bellary Road, Venkatala, Yelahanka, Bangalore - 560063. The board of directors at their meeting held on December 02, 2015 has approved for the same.

This decision was taken following an application to the Drug Controller General of India to withdraw the manufacturing license for Terbutaline Sulphate (TBS). TBS was manufactured predominantly for export and the Company applied to withdraw the manufacturing license for TBS due to low demand for the product in its export markets. Supplies of the product prior to the request for withdrawal of license were manufactured in compliance with GMP standards in those countries in which it was distributed, including India.

The Board took this decision as TBS was the last API to be manufactured at the API Unit and no other API manufacturing activity is planned to be carried out at this unit in the future. The Company's new state of the art tablet manufacturing plant will continue to operate at the above mentioned location. The new tablet manufacturing plant started commercial operations in 2013 and has seen progressive ramping up of production volumes to consistently meet supply requirements.

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.

Astrazeneca Pharma I Share Price

8449.95 -4.45 (-0.05%)
22-Apr-2026 09:20 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1660.00
Dr. Reddys Lab 1210.95
Cipla 1223.30
Zydus Lifesciences 923.70
Lupin 2289.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×